{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:08:13Z","timestamp":1773860893568,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier laboratories","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13054-018-2124-8","type":"journal-article","created":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T08:56:43Z","timestamp":1534323403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Lee S.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Squara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Amour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Carbognani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamel","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Thierry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Apert-Verneuil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Moyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Cholley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"2124_CR1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1161\/CIRCULATIONAHA.106.613596","volume":"117","author":"HR Reynolds","year":"2008","unstructured":"Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008;117:686\u201397.","journal-title":"Circulation"},{"key":"2124_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0022-5223(96)70176-9","volume":"112","author":"V Rao","year":"1996","unstructured":"Rao V, Ivanov J, Weisel RD, Ikonomidis JS, Christakis GT, David TE. Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg. 1996;112:38\u201351.","journal-title":"J Thorac Cardiovasc Surg."},{"key":"2124_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(94)91963-1","volume":"344","author":"S Yusuf","year":"1994","unstructured":"Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the coronary artery bypass graft surgery Trialists collaboration. Lancet. 1994;344:563\u201370.","journal-title":"Lancet"},{"key":"2124_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3346\/jkms.2007.22.2.270","volume":"22","author":"D-K Kim","year":"2007","unstructured":"Kim D-K, Yoo K-J, Hong YS, Chang B-C, Kang M-S. Clinical outcome of urgent coronary artery bypass grafting. J Korean Med Sci. 2007;22:270\u20136.","journal-title":"J Korean Med Sci."},{"key":"2124_CR5","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.athoracsur.2011.06.017","volume":"92","author":"KD Algarni","year":"2011","unstructured":"Algarni KD, Maganti M, Yau TM. Predictors of low cardiac output syndrome after isolated coronary artery bypass surgery: trends over 20 years. Ann Thorac Surg. 2011;92:1678\u201384.","journal-title":"Ann Thorac Surg."},{"key":"2124_CR6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/eurheartj\/ehv051","volume":"36","author":"H Thiele","year":"2015","unstructured":"Thiele H, Ohman EM, Desch S, Eitel I, de Waha S. Management of cardiogenic shock. Eur Heart J. 2015;36:1223\u201330.","journal-title":"Eur Heart J."},{"key":"2124_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1378\/chest.103.1.81","volume":"103","author":"JL Teboul","year":"1993","unstructured":"Teboul JL, Graini L, Boujdaria R, Berton C, Richard C. Cardiac index vs oxygen-derived parameters for rational use of dobutamine in patients with congestive heart failure. Chest. 1993;103:81\u20135.","journal-title":"Chest"},{"key":"2124_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00392-009-0038-9","volume":"98","author":"A Link","year":"2009","unstructured":"Link A, Reil JC, Selejan S, B\u00f6hm M. Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure. Clin Res Cardiol. 2009;98:513\u20135.","journal-title":"Clin Res Cardiol."},{"key":"2124_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00392-011-0375-3","volume":"101","author":"RS Hoke","year":"2012","unstructured":"Hoke RS, M\u00fcller-Werdan U, Lautenschl\u00e4ger C, Werdan K, Ebelt H. Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study. Clin Res Cardiol. 2012;101:139\u201347.","journal-title":"Clin Res Cardiol."},{"key":"2124_CR10","first-page":"H1884","volume":"265","author":"JL Vanoverschelde","year":"1993","unstructured":"Vanoverschelde JL, Wijns W, Essamri B, Bol A, Robert A, Labar D, et al. Hemodynamic and mechanical determinants of myocardial O2 consumption in normal human heart: effects of dobutamine. Am J Phys. 1993;265:H1884\u201392.","journal-title":"Am J Phys."},{"key":"2124_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/ALN.0b013e318173026f","volume":"108","author":"JL Fellahi","year":"2008","unstructured":"Fellahi JL, Parienti JJ, Hanouz JL, Plaud B, Riou B, Ouattara A. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology. 2008;108:979\u201387.","journal-title":"Anesthesiology"},{"key":"2124_CR12","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/ALN.0000000000000224","volume":"120","author":"DV Nielsen","year":"2014","unstructured":"Nielsen DV, Hansen MK, Johnsen SP, Hansen M, Hindsholm K, Jakobsen CJ. Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score-matched analysis. Anesthesiology. 2014;120:1098\u2013108.","journal-title":"Anesthesiology"},{"key":"2124_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/ncpcardio0052","volume":"1","author":"JS Borer","year":"2004","unstructured":"Borer JS. Drug insight: if inhibitors as specific heart-rate-reducing agents. Nat Clin Pract Cardiovasc Med. 2004;1:103\u20139.","journal-title":"Nat Clin Pract Cardiovasc Med."},{"key":"2124_CR14","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0022-2828(03)00150-0","volume":"35","author":"A Bucchi","year":"2003","unstructured":"Bucchi A, Baruscotti M, Robinson RB, DiFrancesco D. I(f)-dependent modulation of pacemaker rate mediated by cAMP in the presence of ryanodine in rabbit sino-atrial node cells. J Mol Cell Cardiol. 2003;35:905\u201313.","journal-title":"J Mol Cell Cardiol."},{"key":"2124_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000073933","volume":"100","author":"M Manz","year":"2003","unstructured":"Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100:149\u201355.","journal-title":"Cardiology"},{"key":"2124_CR16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0022-3565(25)12114-9","volume":"275","author":"L Simon","year":"1995","unstructured":"Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659\u201366.","journal-title":"J Pharmacol Exp Ther."},{"key":"2124_CR17","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","volume":"32","author":"JC Tardif","year":"2011","unstructured":"Tardif JC, O'Meara E, Komajda M, Bohm M, Borer JS, Ford I, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507\u201315.","journal-title":"Eur Heart J."},{"key":"2124_CR18","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.jacc.2013.07.027","volume":"62","author":"JC Reil","year":"2013","unstructured":"Reil JC, Tardif JC, Ford I, Lloyd SM, O'Meara E, Komajda M, et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol. 2013;62:1977\u201385.","journal-title":"J Am Coll Cardiol."},{"key":"2124_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000318530","volume":"116","author":"C Zwicker","year":"2010","unstructured":"Zwicker C, Becker M, Lepper W, Koch KC, Westenfeld R. Cardiogenic shock due to tachycardiomyopathy after heart transplantation: successful treatment with ivabradine. Cardiology. 2010;116:174\u20137.","journal-title":"Cardiology"},{"key":"2124_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijcard.2014.07.093","volume":"176","author":"R Gallet","year":"2014","unstructured":"Gallet R, Ternacle J, Damy T, Guendouz S, Bremont C, Seemann A, et al. Hemodynamic effects of Ivabradine in addition to dobutamine in patients with severe systolic dysfunction. Int J Cardiol. 2014;176:450\u20135.","journal-title":"Int J Cardiol."},{"key":"2124_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2459\/JCM.0000000000000033","volume":"16","author":"Y Cavusoglu","year":"2015","unstructured":"Cavusoglu Y, Mert U, Nadir A, Mutlu F, Morrad B, Ulus T. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure. J Cardiovasc Med (Hagerstown). 2015;16:603\u20139.","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"2124_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/apha.12704","volume":"218","author":"JP Bakkehaug","year":"2016","unstructured":"Bakkehaug JP, Naesheim T, Torgersen Engstad E, Kildal AB, Myrmel T, How OJ. Reversing dobutamine-induced tachycardia using ivabradine increases stroke volume with neutral effect on cardiac energetics in left ventricular post-ischaemia dysfunction. Acta Physiol (Oxf). 2016;218:78\u201388.","journal-title":"Acta Physiol (Oxf)."},{"key":"2124_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/apha.12733","volume":"218","author":"M Akodad","year":"2016","unstructured":"Akodad M, Lim P, Roubille F. Does ivabradine balance dobutamine effects in cardiogenic shock? A promising new strategy. Acta Physiol (Oxf). 2016;218:73\u20137.","journal-title":"Acta Physiol (Oxf)."},{"key":"2124_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ejheart.2008.04.005","volume":"10","author":"GM De Ferrari","year":"2008","unstructured":"De Ferrari GM, Mazzuero A, Agnesina L, Bertoletti A, Lettino M, Campana C, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008;10:550\u20135.","journal-title":"Eur J Heart Fail."},{"key":"2124_CR25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/1053-0770(92)90095-O","volume":"6","author":"JF Butterworth","year":"1992","unstructured":"Butterworth JF, Prielipp RC, Royster RL, Spray BJ, Kon ND, Wallenhaupt SL, et al. Dobutamine increases heart rate more than epinephrine in patients recovering from aortocoronary bypass surgery. J Cardiothorac Vasc Anesth. 1992;6:535\u201341.","journal-title":"J Cardiothorac Vasc Anesth."},{"key":"2124_CR26","first-page":"CD009669","volume":"1","author":"S Unverzagt","year":"2014","unstructured":"Unverzagt S, Wachsmuth L, Hirsch K, Thiele H, Buerke M, Haerting J, et al. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2014;1:CD009669.","journal-title":"Cochrane Database Syst Rev."},{"key":"2124_CR27","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1097\/00000542-199911000-00024","volume":"91","author":"JL Romson","year":"1999","unstructured":"Romson JL, Leung JM, Bellows WH, Bronstein M, Keith F, Moores W, et al. Effects of dobutamine on hemodynamics and left ventricular performance after cardiopulmonary bypass in cardiac surgical patients. Anesthesiology. 1999;91:1318\u201328.","journal-title":"Anesthesiology"},{"key":"2124_CR28","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875\u201385.","journal-title":"Lancet"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-018-2124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13054-018-2124-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-018-2124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T10:22:59Z","timestamp":1751797379000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-018-2124-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2124"],"URL":"https:\/\/doi.org\/10.1186\/s13054-018-2124-8","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,17]]},"assertion":[{"value":"15 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was given by Comit\u00e9 de Protection des Personnes \u201cIle-de-France II\u201d led by Pr. C. Herve on April 16, 2010, under research project number 2010\u201301-02. Consent to participate was given by all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data collected were authorized to be published by participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CA-V and AM are employed by Servier laboratories; they contributed to the study design but did not edit the manuscript. All other authors (LSN, PS, JA, DC, KB, ST, and BC) have no conflict of interest regarding Servier laboratories, including consulting fees and shareholdings.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"193"}}